46 results on '"Ohresser, Marc"'
Search Results
2. Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20
3. Ranibizumab (Lucentis): a New Anti-Angiogenic Treatment in Ophthalmology
4. A robust enzyme-linked immunosorbent assay to measure serum ramucirumab concentrations
5. The case of anti-TNF agents
6. Influence of FCGRT gene polymorphisms on pharmacokinetics of therapeutic antibodies
7. FCGR2C genotyping by pyrosequencing reveals linkage disequilibrium with FCGR3A V158F and FCGR2A H131R polymorphisms in a Caucasian population
8. Transcriptional regulation of the Nia1 gene encoding nitrate reductase in Chlamydomonas reinhardtii: effects of various environmental factors on the expression of a reporter gene under the control of the Nia1 promoter
9. VEGF Polymorphisms are Associated With an Increasing Risk of Developing Renal Cell Carcinoma
10. Interindividual variability in the concentration–effect relationship of antilymphocyte globulins—a possible influence of FcγRIIIa genetic polymorphism
11. Molecular cloning of the Matrix Gla Protein gene from Xenopus laevis: Functional analysis of the promoter identifies a calcium sensitive region required for basal activity
12. Related RNAs in Lepidopteran Cells after in Vitro Infection with Hyposoter didymator Virus Define a New Polydnavirus Gene Family
13. Chapter 14 - The case of anti-TNF agents
14. Implications of receptors for the Fc portion of IgG (Fc gamma Rs) in mechanism of action of therapeutic antibodies
15. Risk in drug trials
16. Evidence for Linkage Disequilibrium Between Fc gamma RIIIa-V158F and Fc gamma RIIa-H131R Polymorphisms in White Patients, and for an Fc gamma RIIIa-Restricted Influence on the Response to Therapeutic Antibodies
17. Fcγ receptor IIIB gene polymorphism is a predictive factor of infectious events under adalimumab in rheumatoid arthritis patients treated in the ReACT study
18. G1m allotypes and development of antibodies-to-infliximab
19. Evidence for linkage disequilibrium between FcyRIIIa-V158F and FcyRIIa-H131R polymorphisms in Caucasians, and for an FcyRIIIa-restricted influence on the response to therapeutic antibodies
20. Influence of FcγRIIIA genetic polymorphism on T-lymphocyte depletion induced by rabbit antithymocyte globulins in kidney transplant patients
21. Influence ofFCGRTgene polymorphisms on pharmacokinetics of therapeutic antibodies
22. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease.
23. FCGR2Cgenotyping by pyrosequencing reveals linkage disequilibrium withFCGR3AV158F andFCGR2AH131R polymorphisms in a Caucasian population
24. Régulation de la transcription de gènes précoces exprimés par le Baculovirus AcMNPV dans des cellules d'insectes
25. FcRn, un récepteur d’IgG aux multiples facettes
26. IgG1 heavy chain-coding gene polymorphism (G1m allotypes) and development of antibodies-to-infliximab
27. Evidence for Linkage Disequilibrium Between FcγRIIIa-V158F and FcγRIIa-H131R Polymorphisms in White Patients, and for an FcγRIIIa-Restricted Influence on the Response to Therapeutic Antibodies
28. FcγRIIIa Expression Is Not Increased on Natural Killer Cells Expressing the FcγRIIIa-158V Allotype
29. Structure–function relationships of the variable domains of monoclonal antibodies approved for cancer treatment
30. Relevance, advantages and limitations of animal models used in the development of monoclonal antibodies for cancer treatment
31. Risk in drug trials
32. No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease
33. Dose-response relationship and pharmacogenetics of anti-RhD monoclonal antibodies
34. Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801A Polymorphism in De Novo Acute Myeloid Leukemia.
35. Persistent expression of a newly characterized Hyposoter didymator polydnavirus gene in long-term infected lepidopteran cell lines
36. Sequence analysis and transcriptional mapping of the orf-2 gene of autographa californica nuclear polyhedrosis virus
37. Influence of FCGRTgene polymorphisms on pharmacokinetics of therapeutic antibodies
38. FCGR2Cgenotyping by pyrosequencing reveals linkage disequilibrium with FCGR3AV158F and FCGR2AH131R polymorphisms in a Caucasian population
39. Related RNAs in Lepidopteran Cells after in VitroInfection with Hyposoter didymatorVirus Define a New Polydnavirus Gene Family
40. CXCL12 polymorphism and malignant cell dissemination/tissue infiltration in acute myeloid leukemia.
41. Sequence analysis and transcriptional mapping of the orf-2 gene of autographa californicanuclear polyhedrosis virus
42. Tumor Cell Dissemination and Tissue Infiltration Are Associated with CXCL12-G801APolymorphism in De Novo Acute Myeloid Leukemia.
43. [Neonatal Fc receptor, key control of immunoglobulins biodistribution].
44. Evidence for linkage disequilibrium between Fcgamma RIIIa-V158F and Fcgamma RIIa-H131R polymorphisms in white patients, and for an Fcgamma RIIIa-restricted influence on the response to therapeutic antibodies.
45. Fc gamma RIIIa expression is not increased on natural killer cells expressing the Fc gamma RIIIa-158V allotype.
46. [Target antigens for therapeutic antibodies in oncology: many candidates, few successes].
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.